» Articles » PMID: 29921698

Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2018 Jun 21
PMID 29921698
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The immunosuppressive microenvironment in glioblastoma (GBM) prevents an efficient antitumoral immune response and enables tumor formation and growth. Although an understanding of the nature of immunosuppression is still largely lacking, it is important for successful cancer treatment through immune system modulation. To gain insight into immunosuppression in GBM, we performed a computational analysis to model relative immune cell content and type of immune response in each GBM tumor sample from The Cancer Genome Atlas RNA-seq data set. We uncovered high variability in immune system-related responses and in the composition of the microenvironment across the cohort, suggesting immunologic diversity. Immune cell compositions were associated with typical alterations such as IDH mutation or inactivating NF1 mutation/deletion. Furthermore, our analysis identified three GBM subgroups presenting different adaptive immune responses: negative, humoral, and cellular-like. These subgroups were linked to transcriptional GBM subtypes and typical genetic alterations. All G-CIMP and IDH-mutated samples were in the negative group, which was also enriched by cases with focal amplification of CDK4 and MARCH9. IDH1-mutated samples showed lower expression and higher DNA methylation of MHC-I-type HLA genes. Overall, our analysis reveals heterogeneity in the immune microenvironment of GBM and identifies new markers for immunosuppression. Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future. This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification. http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg .

Citing Articles

The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.

Vijayanathan Y, Ho I Int J Mol Sci. 2025; 26(2).

PMID: 39859381 PMC: 11765942. DOI: 10.3390/ijms26020669.


Unsupervised clustering reveals noncanonical myeloid cell subsets in the brain tumor microenvironment.

Hermelo I, Virtanen T, Salonen I, Natkin R, Keitaanniemi S, Tiihonen A Cancer Immunol Immunother. 2025; 74(2):63.

PMID: 39751910 PMC: 11699035. DOI: 10.1007/s00262-024-03920-1.


Getting the right combination to break the epigenetic code.

Tolu S, Viny A, Amengual J, Pro B, Bates S Nat Rev Clin Oncol. 2024; 22(2):117-133.

PMID: 39623073 DOI: 10.1038/s41571-024-00972-1.


Investigating the Prognostic and Oncogenic Roles of Membrane-Associated Ring-CH-Type Finger 9 in Colorectal Cancer.

Zhang J, Jiao Q, Chen Z Genet Res (Camb). 2024; 2024:9279653.

PMID: 39185021 PMC: 11344643. DOI: 10.1155/2024/9279653.


Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment Evaluation.

Feng Q, Dong Z, Nie R, Wang X Interdiscip Sci. 2024; 16(3):727-740.

PMID: 38637440 DOI: 10.1007/s12539-024-00627-w.